Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with adriamycin, detorubicin, AD-32, and aclacinomycin.
Golden hamsters received Adriamycin (ADR), detorubicin (DTR), AD-32, or aclacinomycin (ACM) three times weekly at doses extrapolated from optimal doses in L1210 leukemia. Minimal early lesions of the myocardium were detected by electron microscopy in ACM-treated animals. These lesions were aggravated after several weeks of treatment but remained reversible. Lesions in AD-32-treated hamsters were slightly more marked than those seen in ACM-treated animals but were much less severe than those observed in ADR- or DTR-treated animals. Similarly, light microscopy revealed pathologic changes in the skin following ADR or DTR administration. These changes were not seen in animals receiving AD-32 or ACM.
D015250:Aclarubicin / Q000031:analogs & derivatives; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D006224:Cricetinae; D003630:Daunorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D006321:Heart / Q000187:drug effects; D007939:Leukemia L1210 / Q000188:drug therapy; D008647:Mesocricetus; D008854:Microscopy, Electron; D009206:Myocardium / Q000648:ultrastructure*; D009279:Naphthacenes / Q000008:administration & dosage / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects* / Q000473:pathology
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; C011157:aclacinomycins; C016163:valrubicin; D015250:Aclarubicin; D004317:Doxorubicin; D003630:Daunorubicin